NO20080150L - Inhibitorer av AKT-aktivitet - Google Patents

Inhibitorer av AKT-aktivitet

Info

Publication number
NO20080150L
NO20080150L NO20080150A NO20080150A NO20080150L NO 20080150 L NO20080150 L NO 20080150L NO 20080150 A NO20080150 A NO 20080150A NO 20080150 A NO20080150 A NO 20080150A NO 20080150 L NO20080150 L NO 20080150L
Authority
NO
Norway
Prior art keywords
akt activity
inhibitors
akt
compounds
inhibit
Prior art date
Application number
NO20080150A
Other languages
English (en)
Norwegian (no)
Inventor
Jiabing Wang
Donna J Armstrong
Essa H Hu
Michael J Kelly Iii
Mark E Layton
Yiwei Li
Jun Liang
Kevin J Rodzinak
Michael A Rossi
Philip E Sanderson
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20080150L publication Critical patent/NO20080150L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NO20080150A 2005-06-10 2008-01-09 Inhibitorer av AKT-aktivitet NO20080150L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68972605P 2005-06-10 2005-06-10
US73418805P 2005-11-07 2005-11-07
PCT/US2006/022079 WO2006135627A2 (en) 2005-06-10 2006-06-07 Inhibitors of akt activity

Publications (1)

Publication Number Publication Date
NO20080150L true NO20080150L (no) 2008-03-10

Family

ID=37532789

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080150A NO20080150L (no) 2005-06-10 2008-01-09 Inhibitorer av AKT-aktivitet

Country Status (22)

Country Link
US (1) US8008317B2 (es)
EP (1) EP1898903B8 (es)
JP (1) JP5055494B2 (es)
KR (1) KR100959771B1 (es)
AU (1) AU2006258124B8 (es)
BR (1) BRPI0611717A2 (es)
CA (1) CA2610888C (es)
CR (1) CR9580A (es)
DK (1) DK1898903T3 (es)
EC (1) ECSP077980A (es)
ES (1) ES2409168T3 (es)
HR (1) HRP20130429T1 (es)
IL (1) IL187690A (es)
MX (1) MX2007015578A (es)
NI (1) NI200700320A (es)
NO (1) NO20080150L (es)
NZ (1) NZ563423A (es)
PL (1) PL1898903T3 (es)
PT (1) PT1898903E (es)
RU (1) RU2421454C2 (es)
TW (1) TW200800166A (es)
WO (1) WO2006135627A2 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
US8008317B2 (en) 2005-06-10 2011-08-30 Merck Sharp & Dohme Corp. Inhibitors of akt activtiy
TW200806670A (en) * 2006-04-25 2008-02-01 Merck & Co Inc Inhibitors of checkpoint kinases
JP2010512312A (ja) * 2006-12-06 2010-04-22 メルク エンド カムパニー インコーポレーテッド Ａｋｔ活性の阻害剤
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
WO2008118414A1 (en) * 2007-03-28 2008-10-02 Merck & Co., Inc. Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN103396409B (zh) 2007-07-05 2015-03-11 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
PT2188291E (pt) 2007-08-14 2012-12-20 Bayer Ip Gmbh Pirimidinas bicíclicas fundidas
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
CA2726317A1 (en) * 2008-06-03 2009-12-10 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2299825B1 (en) * 2008-06-03 2013-07-31 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2586311B1 (de) 2008-07-17 2016-12-14 Bayer CropScience AG Heterocyclische Verbindungen als Schädlingsbekämpfungsmittel
JP2012516847A (ja) * 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
WO2010091306A1 (en) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
AU2010213192A1 (en) 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
US20130310362A1 (en) 2009-02-13 2013-11-21 Bayer Pharma Aktiegesellschaft Fused pyrimidines
WO2010101734A1 (en) * 2009-03-06 2010-09-10 Merck Sharp & Dohme Corp. Combination cancer therapy with an akt inhibitor and other anticancer agents
WO2010104933A1 (en) * 2009-03-11 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010104705A1 (en) 2009-03-12 2010-09-16 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2266985A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Tricyclic Pyrimidine Derivatives as Wnt antagonists
US8546376B2 (en) 2009-09-18 2013-10-01 Almac Discovery Limited Pharmaceutical compounds
US20120252806A1 (en) * 2009-12-17 2012-10-04 Kelly Iii Michael J Inhibitors of akt activity
GB0922589D0 (en) * 2009-12-23 2010-02-10 Almac Discovery Ltd Pharmaceutical compounds
CN103097384B (zh) * 2010-07-12 2017-02-15 拜耳知识产权有限责任公司 取代的咪唑并[1,2‑a]嘧啶和吡啶
WO2012007500A2 (de) * 2010-07-15 2012-01-19 Bayer Cropscience Ag Neue heterocyclische verbindungen als schädlingsbekämpfungsmittel
SI2694510T1 (sl) 2011-04-07 2016-02-29 Bayer Intellectual Property Gmbh Imidazopiridazini kot inhibitorji AKT kinaze
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN104471070B (zh) * 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
EP3091016A1 (en) * 2015-05-05 2016-11-09 Technische Universität Dortmund Kinase inhibitors and their use in cancer therapy
EP3388428B1 (en) * 2015-12-07 2021-08-04 Suzhou Sinovent Pharmaceuticals Company Five-membered heterocyclic amides wnt pathway inhibitor
TW201822637A (zh) 2016-11-07 2018-07-01 德商拜耳廠股份有限公司 用於控制動物害蟲的經取代磺醯胺類
KR102917509B1 (ko) 2017-09-07 2026-01-26 오거스타 유니버시티 리서치 인스티튜트, 인크. 특이적 akt3 활성제 및 이의 용도
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
WO2023081812A2 (en) * 2021-11-05 2023-05-11 Georgiamune Llc Akt3 modulators
WO2025196160A1 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions
WO2025196161A2 (en) 2024-03-20 2025-09-25 Specialty Operations France Cosmetic compositions, use thereof, and methods for using such compositions

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831013A (en) * 1986-03-20 1989-05-16 Ciba-Geigy Corporation 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines, pharmaceutical compositions, and uses thereof
JP3107827B2 (ja) * 1995-06-06 2000-11-13 ファイザー・インコーポレーテッド トリサイクリック５，６−ジヒドロ−９Ｈ−ピラゾロ［３，４−ｃ］−１，２，４−トリアゾロ［４，３−ａ］ピリジン類
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
GB9824897D0 (en) * 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
US7034026B2 (en) 2001-04-10 2006-04-25 Merck & Co., Inc. Inhibitors of Akt activity
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
CA2480880C (en) 2002-04-08 2011-03-22 Merck & Co., Inc. Inhibitors of akt activity
EP1494675A4 (en) 2002-04-08 2006-07-19 Merck & Co Inc HEMMER OF ACT ACTIVITY
CA2481241C (en) 2002-04-08 2010-07-27 Merck & Co., Inc. Fused quinoxaline derivatives as inhibitors of akt activity
US7223738B2 (en) 2002-04-08 2007-05-29 Merck & Co., Inc. Inhibitors of Akt activity
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
JP2006507299A (ja) 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害薬
ATE461179T1 (de) 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
EP1620095A4 (en) * 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY
CN1809536A (zh) * 2003-04-24 2006-07-26 麦克公司 Akt活性抑制剂
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
EP2468729B1 (en) 2003-10-15 2013-12-25 Ube Industries, Ltd. Novel indazole derivative
AU2005233569B2 (en) 2004-04-09 2010-08-19 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7544677B2 (en) 2004-08-23 2009-06-09 Merck & Co., Inc. Inhibitors of Akt activity
US20080015212A1 (en) 2004-12-02 2008-01-17 Barnett Stanley F Inhibitors Of Akt Activity
US7910561B2 (en) 2004-12-15 2011-03-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101115479A (zh) 2005-02-14 2008-01-30 默克公司 Akt活性抑制剂
CA2602197A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Inhibitors of akt activity
US8008317B2 (en) 2005-06-10 2011-08-30 Merck Sharp & Dohme Corp. Inhibitors of akt activtiy
AR064010A1 (es) 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt

Also Published As

Publication number Publication date
HRP20130429T1 (en) 2013-06-30
AU2006258124A1 (en) 2006-12-21
ES2409168T3 (es) 2013-06-25
NI200700320A (es) 2008-06-17
RU2421454C2 (ru) 2011-06-20
EP1898903B8 (en) 2013-05-15
DK1898903T3 (da) 2013-07-01
WO2006135627A3 (en) 2008-07-31
CR9580A (es) 2008-09-23
EP1898903A2 (en) 2008-03-19
IL187690A (en) 2012-06-28
NZ563423A (en) 2010-05-28
MX2007015578A (es) 2008-03-06
JP2009501698A (ja) 2009-01-22
IL187690A0 (en) 2008-11-03
US8008317B2 (en) 2011-08-30
AU2006258124B2 (en) 2009-09-03
PL1898903T3 (pl) 2013-08-30
EP1898903B1 (en) 2013-03-27
KR100959771B1 (ko) 2010-05-28
WO2006135627A2 (en) 2006-12-21
EP1898903A4 (en) 2010-07-21
CA2610888C (en) 2011-02-08
US20100222321A1 (en) 2010-09-02
TW200800166A (en) 2008-01-01
ECSP077980A (es) 2008-01-23
KR20080016627A (ko) 2008-02-21
RU2008100045A (ru) 2009-07-20
BRPI0611717A2 (pt) 2009-01-13
CA2610888A1 (en) 2006-12-21
PT1898903E (pt) 2013-06-28
JP5055494B2 (ja) 2012-10-24
AU2006258124B8 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
NO20080150L (no) Inhibitorer av AKT-aktivitet
NO20092569L (no) Inhibitorer av Akt-aktivitet
WO2006091395A3 (en) Inhibitors of akt activity
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20061194L (no) Mitotiske kinesininbibitorer
NO20081454L (no) Met-kinaseinhibitorer
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
EA200970486A1 (ru) Соединения для ингибирования митоза
WO2006106326A8 (en) Substituted heterocycles and their use as chk1, pdk1 and pak inhibitors
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
EA201170670A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
NO20091605L (no) Pyridinonforbindelser
NO20073791L (no) Pyrazolylaminopyridinderivater anvendbare som kinaseinhibitorer
NO20073170L (no) Kaspaseinhibitorer og anvendelse derav
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
NO20092691L (no) 4-hydroksy-2-okso-2,3-dihydro-1,3-benzotiazol-7yl-forbindelser for modulering av B2-adrenoreseptoraktivitet
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2006110638A3 (en) Inhibitors of akt activity
ATE443044T1 (de) Tace inhibitoren
NO20064351L (no) Caspaseinhibitorer og anvendelser derav
WO2006068796A3 (en) Inhibitors of akt activity
NO20080839L (no) Isotopsubstituerte protonpumpeinhibitorer
ATE462703T1 (de) Bicyclononen-derivate als renin-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application